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Background: Higher versus lower doses of antiviral drugs used to treat herpes zoster infection may lead to more
adverse drug events in older adults, particularly those with chronic kidney disease.
Methods: We conducted a matched retrospective population-based cohort study of older adults (mean 77 years)
in Ontario, Canada who initiated in the outpatient setting a higher (n = 23,256) or lower (n = 3,876) dose of one of
three oral antivirals for the treatment of herpes zoster between 2002 and 2011. The primary outcome was
hospitalization within 30 days with evidence of a computed tomography (CT) scan of the head (a proxy for acute
neurotoxicity). The secondary outcome was 30-day all-cause mortality.
Results: A higher compared to lower dose of antiviral drug was not associated with an increased risk of
hospitalization with an urgent CT scan of the head (247 [1.06%] events with higher dose versus 43 [1.11%] events
with lower dose, relative risk 0.96, 95% confidence interval 0.69 to 1.33, p-value 0.79) and was not associated with a
higher risk of all-cause mortality (63 [0.27%] events versus 15 [0.39%] events, relative risk 0.70, 95% confidence
interval 0.40 to 1.23, p-value 0.21). Results were consistent in all subgroups, including those with and without
chronic kidney disease.
Conclusions: Initiating a higher compared to a lower dose of an antiviral drug for the treatment of herpes zoster
was not associated with an increased risk of adverse drug events. The findings support the safety of these drugs in
older adults as currently prescribed in routine care.
Keywords: Administrative database, Epidemiology, Mortality, NeurotoxicityBackground
Acyclovir, valacyclovir (a pro-drug which is metabolized to
acyclovir), and famciclovir are prescribed for the treat-
ment of herpes zoster infection [1,2]. These drugs are
commonly prescribed to older adults who are at risk of
dose-related adverse drug reactions, particularly neuroto-
xicity with delirium [3,4]. In older patients with chronic
kidney disease, the recommendation is to reduce the dose
of these drugs to prevent systemic accumulation from* Correspondence: nlam5@uwo.ca
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unless otherwise stated.reduced elimination (Table 1) [5-12]. There have been
many case reports and case series of reversible acute
neurological symptoms, such as delirium, resulting in
hospitalization soon after the initiation of acyclovir, vala-
cyclovir, or famciclovir [13-20]. Whether preferential use
of a low dose of the antiviral drug minimizes this risk is
unknown. Therefore, we conducted this study of older pa-
tients with herpes zoster infection to investigate whether
initiation of a higher rather than lower dose of an oral
antiviral drug in the outpatient setting is associated with
more adverse drug events (neurotoxicity, death) within
30 days of prescription. We also considered whether any
association between dose and adverse events differed in
the presence of chronic kidney disease.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,






(dose in mg/day) [7-9]
Compendium of pharmaceuticals and
specialties (dose in mg/day) [10-12]
Acyclovir 4,000 3,200 4,000 4,000
2,400 CrCl 10–25 mL/min/1.73 m2: 2,400 CrCl 10–25 mL/min/1.73 m2: 2,400
1,600 CrCl <10 mL/min/1.73 m2: 1,600 CrCl <10 mL/min/1.73 m2: 1,600
800
Valacyclovir 3,000 2,000 3,000 3,000
1,500 CrCl 15–30 mL/min: 2,000 CrCl 15–30 mL/min: 2,000
1,000 CrCl <15 mL/min: 1,000 CrCl <15 mL/min: 1,000
500
Famciclovir 1,500 1,000 1,500 1,500
500 CrCl 40–59 mL/min: 1,000 CrCl 40–59 mL/min/1.73 m2: 1,000
350b CrCl 20–39 mL/min: 500 CrCl 20–39 mL/min/1.73 m2: 500
CrCl <20 mL/min: 250 CrCl <20 mL/min/1.73 m2: 250
aDose categories as defined in this study include 50 mg dose above or below the cut-points.
bA dose of 350 mg/day was used instead of 250 mg/day because it was more commonly dispensed in our region with <20 patients being prescribed a dose
of <300 mg/day.
Abbreviation: CrCl Creatinine Clearance.
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Design and setting
We conducted this study at the Institute for Clinical
Evaluative Sciences (ICES) according to a pre-specified
protocol that was approved by the research ethics board
at Sunnybrook Health Sciences Centre (Toronto, Canada).
Participant informed consent was not required for this
study. We conducted a retrospective, population-based,
matched cohort study of older adults using linked health-
care databases in Ontario, Canada. Ontario has appro-
ximately 13 million residents, 2 million of whom are aged
65 years or older [21]. Residents have universal access to
hospital care and physician services and those aged 65
or older have universal prescription drug coverage. The
reporting of this study follows guidelines set out for obser-
vational studies (Additional file 1: Table S1) [22].
Data sources
We ascertained patient characteristics, drug use, covariate
information, and outcome data using records from six da-
tabases. We obtained vital statistics from the Registered
Persons Database (RPDB), which contains demographic
information on all Ontario residents ever issued a health
card. We used the Ontario Drug Benefit (ODB) database
to identify prescription drug use, including dispensing
date, quantity of pills, dose, and number of days supplied.
This database contains highly accurate records of all out-
patient prescriptions dispensed to patients aged 65 years
or older, with an error rate of less than 1% [23]. We identi-
fied diagnostic and procedural information on all hospi-
talizations and emergency room visits from the Canadian
Institute for Health Information Discharge Abstract Data-
base (CIHI-DAD) and the National Ambulatory CareReporting System (NACRS), respectively. We obtained
covariate information from the Ontario Health Insurance
Plan (OHIP) database, which includes health claims for
inpatient and outpatient physician services. We used the
ICES Physician Database (IPDB) to ascertain antiviral
drug prescriber information. Previously, we have used
these databases to research health adverse drug events
and health outcomes, including acyclovir-induced acute
kidney injury [24-26]. With the exception of antiviral pre-
scriber specialty and income quintile (missing in 14.5%
and 0.4% of patients, respectively), the databases were
complete for all variables used in this study. Given the
ability of our databases to capture healthcare activity
province-wide, the only loss to follow-up would be if pa-
tients emigrated from Ontario (a rate estimated to be less
than 1% per year) [27]. The database codes used in the
analysis are defined in Additional file 1: Table S2.
Patients
We established a cohort of residents aged ≥66 years in
Ontario, Canada who filled a new outpatient prescrip-
tion with ≥7-day supply for oral acyclovir, valacyclovir,
or famciclovir from April 2002 to December 2011, a
period spanning 9 years. We restricted our analysis to
those who had evidence of a herpes zoster diagnosis in
the 90 days prior to or 30 days following the time of the
prescription (database diagnosis codes presented in
Additional file 1: Table S2). The date of the first eligible
prescription for a study antiviral served as the index date
for that patient and marked the start date of follow-up.
We excluded the following patients from the analysis: i)
those in their first year of eligibility for prescription drug
coverage (age 65) to avoid incomplete medication records,
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may have frequent episodes of confusion or delirium for
many reasons, iii) those with end-stage renal disease, iv)
those who had a prescription for any antiviral in the prior
180 days in order to capture new usage, v) those who had
a prescription for more than one type of antiviral on the
index date in order to compare mutually exclusive groups,
and vi) those who had a hospital admission or discharge
on their index date or a hospital discharge in the prior
two days to ensure these were new outpatient antiviral
prescriptions (as patients continuing an antiviral treat-
ment initiated in hospital would have their outpatient
antiviral prescription dispensed on the same or next day
of hospital discharge).
To select two groups of antiviral users that were well-
balanced on the baseline characteristics we measured in
this study, we matched each low-dose user with a high-
dose user on a 1:6 basis using the following variables:
age (within two years), sex, presence of chronic kidney
disease, and type of antiviral prescribed (acyclovir, vala-
cyclovir, or famciclovir). In Ontario, the validated algo-
rithm for chronic kidney disease identifies older adults
with a median estimated glomerular filtration rate
(eGFR) of 38 mL/min per 1.73 m2 (interquartile range
27 to 52), whereas its absence identifies those with a me-
dian eGFR of 69 mL/min per 1.73 m2 (interquartile
range 56 to 82) [28].
Antiviral dose
To align with recommendations in drug prescribing re-
ferences, a higher dose of antiviral therapy was defined
as at least 4,000 mg/day for acyclovir, 3,000 mg/day for
valacyclovir, and 1,500 mg/day for famciclovir. A lower
dose of antiviral therapy was defined as 3,200 mg/day,
2,400 mg/day, 1,600 mg/day or 800 mg/day for acyclovir,
2,000 mg/day, 1,500 mg/day, 1,000 mg/day, or 500 mg/day
for valacyclovir, and 1,000 mg/day, 500 mg/day, or
350 mg/day for famciclovir (Table 1).
Outcomes
We followed all patients for 30 days after the index date
for the assessment of two pre-specified outcomes. The
primary outcome was hospital admission with evidence
of an urgent computed tomography (CT) scan of the
head within the first five days of admission (inclusive of
any scans performed in the emergency room preceding
an admission). Based on prospective studies of common
clinical practice, neuroimaging is frequently used in the
routine evaluation of patients who present to hospital
acutely confused, even among those without focal neu-
rological findings or head trauma [29-31]. Unlike diag-
nostic codes for acute delirium, the receipt of a CT scan
of the head is well coded in our data sources (these
codes have high sensitivity and specificity for receipt ofthe imaging as they are associated with physician reim-
bursement) [32]. We also expected urgent CT scans of
the head conducted for reasons unrelated to antiviral
dosing to occur at a similar frequency in higher and
lower dose groups; therefore, not impacting estimates of
difference in risk. We have used this outcome of urgent
CT scans of the head in other population-based drug
safety studies to characterize the risk of drug-induced
delirium [33]. Our secondary outcome was all-cause
mortality. Death is accurately coded in our data sources
(sensitivity 94%, positive predictive value 100%) [34].
Statistical analysis
We compared baseline characteristics between those pre-
scribed a higher or lower antiviral dose using standardized
differences [35]. This metric describes differences between
group means relative to the pooled standard deviation and
is considered a meaningful difference if greater than 10%.
We estimated the odds ratio and 95% confidence intervals
for inpatient CT scan of the head with higher antiviral
dose compared to lower antiviral dose using conditional
logistic regression analyses (accounting for matched sets).
We interpreted odds ratios as relative risks which was ap-
propriate given the low incidence of observed events. We
examined the relative risk between higher dose and lower
dose (referent dose) antiviral and each outcome first in
the entire matched cohort and then in four pre-defined
subgroups based on: age, sex, presence of chronic kidney
disease, and antiviral type. We examined whether relative
risks differed among subgroups using tests for inter-
action. We conducted all analysis with Statistical Analysis
Software (SAS) version 9.2 (SAS Institute Incorporated,
Cary, North Carolina, USA, 2008).
Results
We identified 77,381 eligible older adults who were pre-
scribed outpatient oral antiviral drug for the treatment of
herpes zoster infection (higher dose, n = 73,383 versus
lower dose, n = 3,998). After the match, there were a total
of 27,132 eligible patients of which 23,256 (85.7%) received
a higher antiviral dose and 3,876 (14.3%) received lower
antiviral dose (referent dose). A diagram of the cohort se-
lection is represented in Additional file 1: Figure S1. The
baseline characteristics of patients before and after the
match are presented in Table 2. After the match, the base-
line characteristics of the two dose groups were nearly
identical (all standardized differences for 17 measured
variables between the groups were ≤8%). The mean age
was 77 years (standard deviation 7.1 years) and 63% were
women. Three-quarters of the prescriptions were written
by primary care physicians with 67% of prescriptions writ-
ten for valacyclovir. Ophthalmologist prescribed <1% of
the antivirals and <0.3% of patients had a diagnosis for
herpes zoster involving the eye.















Age, years 75.9 [6.8] 77.0 [7.3] 0.15 76.7 [7.1] 76.7 [7.1] 0
Women 45,613 (62.2) 2,541 (63.6) 0.03 14,682 (63.1) 2,447 (63.1) 0
Year of cohort entry
2002 - 2003 11,318 (15.4) 514 (12.9) 0.07 3,083 (13.3) 505 (13.0) 0.01
2004 - 2005 14,016 (19.1) 595 (14.9) 0.11 4,096 (17.6) 572 (14.8) 0.08
2006 - 2007 14,930 (20.3) 807 (20.2) 0 4,641 (20.0) 779 (20.1) 0
2008 - 2009 15,783 (21.5) 993 (24.8) 0.08 5,320 (22.9) 964 (24.9) 0.05
2010 - 2011 17,336 (23.6) 1,089 (27.2) 0.08 6,116 (26.3) 1,056 (27.2) 0.02
Income quintiled
First (lowest) 13,937 (19.0) 831 (20.8) 0.04 4,404 (18.9) 804 (20.7) 0.05
Second 15,526 (21.2) 802 (20.1) 0.03 4,886 (21.0) 777 (20.1) 0.02
Third (middle) 14,231 (19.4) 842 (21.1) 0.04 4,469 (19.2) 818 (21.1) 0.05
Fourth 14,521 (19.8) 751 (18.8) 0.03 4,620 (19.9) 730 (18.8) 0.03
Fifth (highest) 14,976 (20.4) 755 (18.9) 0.04 4,808 (20.7) 731 (18.9) 0.05
Missing 192 (0.26) 17 (0.43) 0.03 69 (0.3) 16 (0.4) 0.02
Rural locatione 10,864 (14.8) 505 (12.6) 0.06 3,027 (13.0) 491 (12.7) 0.01
Modified Charlson scoref
0 53,431 (72.8) 2,731 (68.3) 0.10 16,623 (71.5) 2,684 (69.3) 0.05
1 8,024 (10.9) 445 (11.1) 0.01 2,560 (11.0) 428 (11.0) 0
2 6,350 (8.7) 400 (10.0) 0.05 2,086 (9.0) 383 (9.9) 0.03
≥3 5,578 (7.6) 422 (10.6) 0.10 1,987 (8.5) 381 (9.8) 0.04
Co-morbiditiesg
CKDh 3,799 (5.2) 425 (10.6) 0.20 1,896 (8.2) 316 (8.2) 0
Chronic liver disease 2,420 (3.3) 138 (3.5) 0.01 735 (3.2) 135 (3.5) 0.02
COPD 2,994 (4.1) 212 (5.3) 0.06 1,010 (4.3) 198 (5.1) 0.04
CADi 25,840 (35.2) 1,548 (38.7) 0.07 8,427 (36.2) 1,478 (38.1) 0.04
Diabetes mellitusj 11,016 (15.0) 699 (17.5) 0.07 3,636 (15.6) 671 (17.3) 0.05
Heart failure 8,469 (11.5) 611 (15.3) 0.11 2,985 (12.8) 571 (14.7) 0.06
Stroke/TIA 1,556 (2.1) 109 (2.7) 0.04 513 (2.2) 99 (2.6) 0.02
Herpes zoster (eye) 89 (0.12) 8 (0.20) 0.02 30 (0.13) 8 (0.21) 0.02
Antiviral type
Acyclovir 4,095 (5.6) 297 (7.4) 0.08 1,692 (7.3) 282 (7.3) 0
Valacyclovir 29,482 (40.2) 2,694 (67.4) 0.57 15,528 (66.8) 2,588 (66.8) 0
Famciclovir 39,806 (54.2) 1,007 (25.2) 0.62 6,036 (26.0) 1,006 (26.0) 0
Medicationsk
Anticonvulsants 3,079 (4.2) 178 (4.5) 0.01 988 (4.3) 167 (4.3) 0
Gabapentin 420 (0.57) 24 (0.60) 0 137 (0.59) 22 (0.57) 0
Antidepressants 11,201 (15.3) 663 (16.6) 0.04 3,756 (16.2) 636 (16.4) 0.01
Antipsychotics 1,431 (2.0) 88 (2.2) 0.02 503 (2.2) 86 (2.2) 0
Barbituates 115 (0.16) 7 (0.18) 0 45 (0.19) 7 (0.18) 0
Benzodiazepines 13,794 (18.8) 809 (20.2) 0.04 4,446 (19.1) 774 (20.0) 0.02
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Table 2 Baseline characteristics (Continued)
Histamine2-receptor antagonists 6,191 (8.4) 337 (8.4) 0 1,911 (8.2) 325 (8.4) 0.01
Dopamine agonists 326 (0.44) 22 (0.55) 0.02 124 (0.53) 22 (0.57) 0
Muscle relaxants 399 (0.54) 25 (0.63) 0.01 132 (0.57) 25 (0.64) 0.01
Opioids 15,738 (21.5) 957 (23.9) 0.06 5,076 (21.8) 923 (23.8) 0.05
Overactive bladder medications 2,169 (3.0) 149 (3.7) 0.04 704 (3.0) 142 (3.7) 0.04
Prescribing physician
General practitioner 55,723 (75.9) 3,015 (75.4) 0.01 17,671 (76.0) 2,925 (75.5) 0.01
Ophthalmologist 272 (0.37) 28 (0.70) 0.05 90 (0.39) 27 (0.70) 0.04
Neurologistl 41 (0.06) ≤5 ( − ) ( − ) 12 (0.05) ≤5 ( − ) ( − )
Other 7,538 (10.3) 372 (9.3) 0.03 2,350 (10.1) 360 (9.3) 0.03
Missing 9,809 (13.4) 581 (14.5) 0.03 3,133 (13.5) 562 (14.5) 0.03
Data presented as number (percent) except for age which is presented as mean [standard deviation].
Abbreviations: CAD Coronary Artery Disease, CKD Chronic Kidney Disease, COPD Chronic Obstructive Pulmonary Disease, TIA Transient Ischemic Attack.
aHigher dose of antiviral defined as 4,000 mg/day for acyclovir, 3,000 mg/day for valacyclovir, and 1,500 mg/day for famciclovir.
bA lower dose of antiviral defined as 3,200 mg/day, 2,400 mg/day, 1,600 mg/day or 800 mg/day for acyclovir, 2,000 mg/day, 1,500 mg/day, 1,000 mg/day, or
500 mg/day for valacyclovir, and 1,000 mg/day, 500 mg/day, or 350 mg/day for famciclovir.
cStandardized differences are less sensitive to sample size than traditional hypothesis tests. They provide a measure of the difference between groups divided by
the pooled standardized difference; a value >10% (0.1) is interpreted as a meaningful difference between the groups [35].
dIncome was categorized into quintiles based on average neighbourhood income on the index date.
eRural location indicates a population <10,000.
fAssessed with an algorithm using diagnosis codes from hospitalizations in the five years prior; patients with no hospitalizations during this period were given a
value of zero.
gCo-morbid diagnoses were ascertained from administrative database codes in the five years preceding the index date.
hIdentified individuals with chronic kidney disease using an algorithm of diagnosis codes validated in our region for older adults [28]. The algorithm identified
patients with a median estimated glomerular filtration rate (eGFR) of 38 mL/min per 1.73 m2 (interquartile range 27 to 52), whereas its absence identified patients
with a median eGFR of 69 mL/min per 1.73 m2 (interquartile range 56 to 82).
iCoronary artery disease includes receipt of coronary artery bypass graft surgery, percutaneous coronary intervention, and diagnoses of angina.
jIdentified individuals with diabetes through medication use including oral hypoglycemic and insulin.
kMedication use was assessed in the 180 days prior to the index date.
lDue to privacy issues, values ≤5 are suppressed.
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higher antiviral dose was not associated with a higher
risk of hospitalization with urgent CT scan of the head
(247 [1.06%] events with higher dose versus 43 [1.11%]
events with lower dose, relative risk 0.96, 95% con-
fidence interval 0.69 to 1.33, p-value 0.79) (Table 3).
Figure 1 presents the association between antiviral dose
and the primary outcome in four pre-defined subgroups:
by age, sex, presence of chronic kidney disease, and anti-
viral type. There was no association between antiviral
dose and hospital admission with urgent CT scan of the
head in any of the subgroups, including those with and
without chronic kidney disease (p-value for interaction
0.25). There was also no difference between the two




Hospital admission with urgent CT scan of the head 247 (1.06%)
All-cause mortality 63 (0.27%)
Abbreviations: CT, Computed Tomography.
aHigher dose of antiviral defined as 4,000 mg/day for acyclovir, 3,000 mg/day for va
bA lower dose of antiviral defined as 3,200 mg/day, 2,400 mg/day, 1,600 mg/day or
500 mg/day for valacyclovir, and 1,000 mg/day, 500 mg/day, or 350 mg/day for fam(63 [0.27%] events with higher dose versus 15 [0.39%]
events with lower dose, relative risk 0.70, 95% confi-
dence interval 0.40 to 1.23, p-value 0.21) (Table 3).Discussion
In this population-based study of over 27,000 older pa-
tients, we found no association between initiating oral
antiviral treatment for herpes zoster at a higher versus
lower dose and the risk of hospital admission within
30 days with evidence of an urgent CT scan of the head.
A similar association was observed in patients with and
without chronic kidney disease, although given the
smaller number of patients with chronic kidney disease,
the estimates were less precise with wider confidenceT scan of the head and all-cause mortality
events (Percent) Relative risk P-value
Lower doseb
(Referent) (n = 3,876)
[95% confidence interval]
43 (1.11%) 0.96 [0.69 to 1.33] 0.79
15 (0.39%) 0.70 [0.40 to 1.23] 0.21
lacyclovir, and 1,500 mg/day for famciclovir.
800 mg/day for acyclovir, 2,000 mg/day, 1,500 mg/day, 1,000 mg/day, or
ciclovir.
Figure 1 Subgroup analysis of the risk of hospital admission with urgent CT scan of the head.
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rent between the two dose groups.
Acyclovir, valacyclovir, and famciclovir are commonly
prescribed antivirals used in routine outpatient care for
the treatment of herpes zoster infection in the elderly. In
randomized controlled trials, these drugs are similarly
effective in reducing the duration and severity of painful
lesions, preventing complications, and decreasing the
frequency of recurrence [1,2]. A known adverse event of
these oral antiviral drugs is neurotoxicity [13-20]. The
symptoms of drug-induced neurotoxicity include tremor,
confusion, hallucinations, and coma and can often be
difficult to distinguish from herpes encephalitis. With
these antivirals, symptoms typically occur within days of
drug initiation and generally resolve with drug discon-
tinuation. In one case series of 35 patients with neuro-
psychiatric symptoms during acyclovir treatment, risk
factors included older age, the presence of chronic kid-
ney disease, and co-administration of other potentially
neurotoxic medications [13].
Given the results of these prior pharmacokinetic stu-
dies and case reports, we were concerned we would ob-
serve an increased risk of major adverse events when a
higher rather than lower dose of an antiviral drug was
initiated in older adults, particularly those with con-
comitant chronic kidney disease. The findings from thisstudy are reassuring and support the safety of these drugs
in older adults as currently prescribed in routine care.
Our study has a number of strengths. To our know-
ledge, it is the first population-based assessment of ad-
verse outcomes from higher dose versus lower dose
antiviral treatment. The study was made possible by our
province’s universal health care benefits, which provides
information on all health care encounters for all Ontarians
including accurate records of outpatient prescriptions to
older patients. Consequently, there were a large number
of patients who received antiviral prescriptions and this
provided good precision for the estimates obtained for the
primary outcome (there were over 200 events and the
95% confidence interval for the point estimate of the pri-
mary outcome was 0.69 to 1.33; confidently ruling out a
1.4 or higher risk).
Our study does have some limitations. For reasons of
feasibility, in this retrospective study, we relied on ur-
gent neuroimaging within the available data sources as a
proxy for the diagnosis of acute altered mental status. A
preferred methodology would be a prospective study
with independent blinded outcome adjudication and de-
tailed serial measures of cognitive function. In such an
effort, kidney function values could also be recorded,
rather than a validated algorithm for chronic kidney
disease as used in our study. We were encouraged by
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after matching and in the consistency of the observed
association among various subgroups. However, in our
study the antiviral dose was not randomly assigned, and
with all observational studies, we may have failed to ac-
count for important unknown or unmeasured confoun-
ding variables. Our cohort consisted of patients over the
age of 65 years. It is reassuring that 99% of elderly
patients in routine care did not present to hospital with
urgent CT scan of the head after use of either dose of
oral antivirals. While we did not study younger patients
in the present study, their incidence of adverse events
would be expected to be even less.Conclusions
In this study, initiating a higher compared to a lower
dose of an antiviral drug for the treatment of herpes zos-
ter was not associated with an increased risk of adverse
drug events. The findings support the safety of these
drugs in older adults as currently prescribed in routine
care.Additional file
Additional file 1: Table S1. STROBE checklist. Table S2. Databases and
coding definitions for baseline characteristics and study outcomes.
Figure S1. Cohort selection.
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